{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T00:17:06Z","timestamp":1758586626035,"version":"3.44.0"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T00:00:00Z","timestamp":1758499200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Naltrexone is a pharmacological intervention widely used for alcohol use disorder (AUD), opioid use disorder (OUD), and several off-label conditions. Systematic reviews (SRs) play a critical role in synthesizing data on the efficacy and safety of such interventions to inform clinical guidelines and decision-making. However, adequate reporting of harms in SRs remains inconsistent, limiting the ability to fully assess the safety profile of naltrexone. This study evaluates completeness of harms reporting and methodological quality in SRs focusing on naltrexone.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A comprehensive search of MEDLINE, EMBASE, Epistemonikos, and the Cochrane Database of Systematic Reviews was conducted. The study employed masked, duplicate screening and data extraction. Included SRs were evaluated for completeness of harms reporting using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) harms checklist and other established frameworks. Methodological quality was appraised using the A MeaSurement Tool to Assess Systematic Reviews-2 (AMSTAR-2) tool, and primary study overlap among SRs was assessed through corrected covered area (CCA) analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 87 SRs were included in the analysis. Only 1.1% (1\/87) utilized severity scales to classify harms, and 4.6% (4\/87) defined harms in their methods. Nearly half (48.3%) of SRs failed to address harms as either a primary or secondary outcome. A total of 82.8% (72\/87) of SRs were rated as \u201ccritically low\u201d quality by AMSTAR-2. Statistical analysis revealed a significant relationship between \u201ccritically low\u201d AMSTAR-2 ratings and incomplete harms reporting (<jats:italic>p<\/jats:italic> = 0.0486). Additionally, four SR pairs demonstrated \u201chigh\u201d overlap (&amp;gt;50%) of primary studies, accompanied by inconsistencies in harms reporting.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our findings underscore the critical need for improved and standardized harms reporting in SRs on naltrexone. Inconsistent and incomplete reporting limits the ability of clinicians to fully assess the safety profile of naltrexone within systematic reviews. Adopting established frameworks such as PRISMA harms extensions and severity scales is imperative to enhance transparency and reliability in SRs. This study advocates for methodological improvements in SRs to support comprehensive safety evaluations and evidence-based prescribing of naltrexone.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fpsyt.2025.1597019","type":"journal-article","created":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T05:29:30Z","timestamp":1758518970000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Reporting of harms in systematic reviews focused on naltrexone: a cross-sectional study"],"prefix":"10.3389","volume":"16","author":[{"given":"Joseph","family":"Schnitker","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lindsey","family":"Purcell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morgan","family":"Garrett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Holly","family":"Flores","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Audrey","family":"Wise","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Micah","family":"Kee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brayden","family":"Rucker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason","family":"Beaman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matt","family":"Vassar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,22]]},"reference":[{"key":"B1","volume-title":"Chapter 3C: Naltrexone","year":"2018"},{"key":"B2","unstructured":"Stewart\n              J\n            \n          \n          Auckland, New Zealand\n          Drugs.com\n          Vivitrol (naltrexone) FDA Approval History\n          \n          2021"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-0946-y","article-title":"Centrally acting agents for obesity: Past, present, and future","volume":"78","author":"Coulter","year":"2018","journal-title":"Drugs"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.12.031","article-title":"The uses of naltrexone in dermatologic conditions","volume":"80","author":"Lee","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1097\/00000374-199708000-00020","article-title":"Naltrexone biotransformation and incidence of subjective side effects: a preliminary study","volume":"21","author":"King","year":"1997","journal-title":"Alcohol Clin Exp Res"},{"key":"B6","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1136\/bmj.323.7312.546","article-title":"Assessment of therapeutic safety in systematic reviews: literature review","volume":"323","author":"Ernst","year":"2001","journal-title":"BMJ"},{"key":"B7","doi-asserted-by":"publisher","first-page":"c365","DOI":"10.1136\/bmj.c365","article-title":"The impact of outcome reporting bias in randomized controlled trials on a cohort of systematic reviews","volume":"340","author":"Kirkham","year":"2010","journal-title":"BMJ"},{"key":"B8","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/1471-2288-4-19","article-title":"Assessing harmful effects in systematic reviews","volume":"4","author":"McIntosh","year":"2004","journal-title":"BMC Med Res Methodol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2021.10.023","article-title":"Harms in systematic reviews paper 1: An introduction to research on harms","volume":"143","author":"Qureshi","year":"2022","journal-title":"J Clin Epidemiol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/2046-4053-4-1","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement","volume":"4","author":"Moher","year":"2015","journal-title":"Syst Rev"},{"key":"B11","article-title":"Family physicians\u2019 use of medical abstracts to guide decision making: style or substance","volume":"14","author":"Barry","year":"2001","journal-title":"J Am Board Fam Pract"},{"key":"B12","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1136\/eb-2012-100537","article-title":"A comparison of the accuracy of clinical decisions based on full-text articles and journal abstracts alone: a study among residents in a tertiary care hospital","volume":"18","author":"Marcelo","year":"2013","journal-title":"Evid Based Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1136\/bmjebm-2018-110995","article-title":"Developing tools to enhance the use of systematic reviews for clinical care in health systems","volume":"23","author":"Morrow","year":"2018","journal-title":"BMJ Evid Based Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1844","article-title":"Systematic reviews of adverse effects of drug interventions: a survey of their conduct and reporting quality","volume":"18","author":"Cornelius","year":"2009","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"B15","doi-asserted-by":"publisher","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"key":"B16","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"B17","doi-asserted-by":"publisher","first-page":"i157","DOI":"10.1136\/bmj.i157","article-title":"PRISMA harms checklist: improving harms reporting in systematic reviews","volume":"352","author":"Zorzela","year":"2016","journal-title":"BMJ"},{"key":"B18","volume-title":"Naltrexone. Open Science Framework","author":"Wise","year":"2022"},{"key":"B19","unstructured":"Introduction to Systematic Review and Meta-Analysis"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1136\/bmjebm-2019-111233","article-title":"Treating schizophrenia: the quality of evidence behind treatment recommendations and how it can improve","volume":"25","author":"Aran","year":"2020","journal-title":"BMJ Evid Based Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/anae.13520","article-title":"Risk of bias and methodological appraisal practices in systematic reviews published in anaesthetic journals: a meta-epidemiological study","volume":"71","author":"Detweiler","year":"2016","journal-title":"Anaesthesia"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.bja.2021.08.016","article-title":"Methodological quality of systematic reviews comprising clinical practice guidelines for cardiovascular risk assessment and management for noncardiac surgery","volume":"127","author":"Jacobsen","year":"2021","journal-title":"Br J Anaesth"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajem.2017.06.010","article-title":"Variable methodological quality and use found in systematic reviews referenced in STEMI clinical practice guidelines","volume":"35","author":"Scott","year":"2017","journal-title":"Am J Emerg Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2014.06.016","article-title":"Side effects are incompletely reported among systematic reviews in gastroenterology","volume":"68","author":"Mahady","year":"2015","journal-title":"J Clin Epidemiol"},{"key":"B25","volume-title":"Summaries of harms in systematic reviews are unreliable (Part 1 of 2): Methods used to assess harms are neglected in systematic reviews of gabapentin","author":"Qureshi","year":"2021"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2021.10.025","article-title":"Summaries of harms in systematic reviews are unreliable Paper 3: Given the same data sources, systematic reviews of gabapentin have different results for harms","volume":"143","author":"Qureshi","year":"2021","journal-title":"J Clin Epidemiol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.1390","article-title":"Examining overlap of included studies in meta-reviews: Guidance for using the corrected covered area index","volume":"11","author":"Hennessy","year":"2020","journal-title":"Res Synth Methods"},{"key":"B28","doi-asserted-by":"publisher","first-page":"j4008","DOI":"10.1136\/bmj.j4008","article-title":"AMSTAR 2: a critical appraisal tool for systematic reviews that include randomized or non-randomized studies of healthcare interventions, or both","volume":"358","author":"Shea","year":"2017","journal-title":"BMJ"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2004.04.026","article-title":"Availability of large-scale evidence on specific harms from systematic reviews of randomized trials","volume":"117","author":"Papanikolaou","year":"2004","journal-title":"Am J Med"},{"key":"B30","unstructured":""},{"key":"B31","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.jaad.2017.08.024","article-title":"Psychiatric adverse events during treatment with brodalumab: Analysis of psoriasis clinical trials","volume":"78","author":"Lebwohl","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1002\/cpp.1765","article-title":"How to define, find and classify side effects in psychotherapy: from unwanted events to adverse treatment reactions","volume":"20","author":"Linden","year":"2013","journal-title":"Clin Psychol Psychother"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-141-10-200411160-00009","article-title":"Better reporting of harms in randomized trials: an extension of the CONSORT statement","volume":"141","author":"Ioannidis","year":"2004","journal-title":"Ann Intern Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1136\/jamia.2010.006882","article-title":"Development of a combined system for identification and classification of adverse drug reactions: Alerts Based on ADR Causality and Severity (ABACUS)","volume":"17","author":"Koh","year":"2010","journal-title":"J Am Med Inform Assoc"},{"key":"B35","doi-asserted-by":"publisher","first-page":"2050312117690404","DOI":"10.1177\/2050312117690404","article-title":"Assessment of the expectancy, seriousness and severity of adverse drug reactions reported for chronic obstructive pulmonary disease therapy","volume":"5","author":"Petrova","year":"2017","journal-title":"SAGE Open Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-141-10-200411160-00009","article-title":"CONSORT Group. Better reporting of harms in randomized trials: an extension of the CONSORT statement","volume":"141","author":"Ioannidis","year":"2004","journal-title":"Ann Intern Med"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2023.04.005","article-title":"CONSORT Harms Group. CONSORT Harms 2022 statement, explanation, and elaboration: updated guideline for reporting harms in randomized trials","volume":"158","author":"Junqueira","year":"2023","journal-title":"J Clin Epidemiol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i157","article-title":"PRISMA Harms Group. PRISMA harms checklist: improving harms reporting in systematic reviews","volume":"352","author":"Zorzela","year":"2016","journal-title":"BMJ"},{"key":"B39","article-title":"Chapter 19: adverse effects","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions. Version 6.5","author":"Peryer","year":"2024"},{"key":"B40","unstructured":"Bethesda, MD, USA\n          National Cancer Institute\n          Common Terminology Criteria for Adverse Events (CTCAE). Version 5.0\n          \n          2017"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2011.10111704","article-title":"The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults","volume":"168","author":"Posner","year":"2011","journal-title":"Am J Psychiatry"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2025.1597019\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T05:29:32Z","timestamp":1758518972000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2025.1597019\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,22]]},"references-count":42,"alternative-id":["10.3389\/fpsyt.2025.1597019"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2025.1597019","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,22]]},"article-number":"1597019"}}